UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
August 10, 2004
Vicuron Pharmaceuticals Inc.
(Exact Name of Registrant As Specified in its Charter)
Delaware | 000-31145 | 04-3278032 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
455 South Gulph Road, Suite 305, King of Prussia, PA 19406
(Address of Principal Executive Offices) (Zip Code)
(610) 205-2300
(Registrants telephone number, including area code)
not applicable
(Former Name or Former Address, if Changed Since Last Report.)
Item 5. Other Events and Required FD Disclosure.
On August 10, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing that it recently completed a Phase II trial of Ramoplanin for the treatment of Clostridium difficile-associated diarrhea (CDAD).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VICURON PHARMACEUTICALS INC. | ||||
(Registrant) | ||||
Date: August 11, 2004 |
By: |
/s/ George F. Horner III | ||
George F. Horner III | ||||
President and Chief Executive Officer |